Anti-prolactin treatment alleviates lupus conditions by regulating the JAK2-STAT3 pathway.

Jiang, Ying; Chen, Huyan; Lin, Jinran; Pan, Jiewen; Shen, Yanyun; Li, Qiao

Jiang, Ying; Chen, Huyan; Lin, Jinran; Pan, Jiewen; Shen, Yanyun; Li, Qiao.

Afiliação

Jiang Y; Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Chen H; Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology, Shanghai, People's Republic of China.
Lin J; Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology, Shanghai, People's Republic of China.
Pan J; Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology, Shanghai, People's Republic of China.
Shen Y; Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology, Shanghai, People's Republic of China.
Li Q; Department of Dermatology, Huashan Hospital, Fudan University, Shanghai Institute of Dermatology, Shanghai, People's Republic of China.

Clin Exp Pharmacol Physiol ; 50(12): 936-943, 2023 12.

Article em En | MEDLINE | ID: mdl-37727880

Assuntos

Nefrite Lúpica; Linfadenopatia; Humanos; Animais; Camundongos; Prolactina/metabolismo; Prolactina/uso terapêutico; Esplenomegalia; Camundongos Endogâmicos MRL lpr; Nefrite Lúpica/tratamento farmacológico; Nefrite Lúpica/patologia; Modelos Animais de Doenças; Janus Quinase 2/metabolismo; Fator de Transcrição STAT3/metabolismo

Palavras-chave

MRL/lpr mice; prolactin; systemic lupus erythematosus; therapeutic strategies

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nefrite Lúpica / Linfadenopatia Limite: Animals / Humans Idioma: En Revista: Clin Exp Pharmacol Physiol Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google